Unichem Laboratories Limited Logo

Unichem Laboratories Limited

UNICHEMLAB.NS

(1.2)
Stock Price

648,20 INR

-4.35% ROA

1.2% ROE

-24.26x PER

Market Cap.

32.365.546.260,00 INR

12.05% DER

0% Yield

0.87% NPM

Unichem Laboratories Limited Stock Analysis

Unichem Laboratories Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Unichem Laboratories Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (13%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.14x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (3.716), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

5 ROE

Negative ROE (-7.9%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-6.1%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Unichem Laboratories Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Unichem Laboratories Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Unichem Laboratories Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Unichem Laboratories Limited Revenue
Year Revenue Growth
2005 5.472.620.000
2006 6.279.390.000 12.85%
2007 6.713.490.000 6.47%
2008 7.352.336.000 8.69%
2009 7.473.860.000 1.63%
2010 8.240.381.000 9.3%
2011 8.754.630.000 5.87%
2012 10.808.028.000 19%
2013 11.334.479.000 4.64%
2014 12.017.934.000 5.69%
2015 13.345.638.000 9.95%
2016 15.195.041.000 12.17%
2017 7.781.346.000 -95.28%
2018 11.227.701.000 30.7%
2019 11.564.925.000 2.92%
2020 11.899.183.000 2.81%
2021 12.479.820.000 4.65%
2022 13.430.222.000 7.08%
2023 16.625.160.000 19.22%
2023 17.048.947.000 2.49%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Unichem Laboratories Limited Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 321.500.000 100%
2008 272.130.000 -18.14%
2009 291.178.000 6.54%
2010 383.512.000 24.08%
2011 392.737.000 2.35%
2012 364.932.000 -7.62%
2013 521.510.000 30.02%
2014 464.214.000 -12.34%
2015 438.677.000 -5.82%
2016 616.938.000 28.89%
2017 849.686.000 27.39%
2018 1.163.588.000 26.98%
2019 1.564.075.000 25.61%
2020 439.020.000 -256.27%
2021 337.564.000 -30.06%
2022 263.939.000 -27.89%
2023 0 0%
2023 1.046.670.000 100%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Unichem Laboratories Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 4.585.990.000
2006 5.352.350.000 14.32%
2007 5.528.410.000 3.18%
2008 5.658.312.000 2.3%
2009 5.474.153.000 -3.36%
2010 6.356.099.000 13.88%
2011 979.074.000 -549.19%
2012 941.000 -103946.12%
2013 209.012.000 99.55%
2014 2.255.853.000 90.73%
2015 295.782.000 -662.67%
2016 304.981.000 3.02%
2017 236.422.000 -29%
2018 341.094.000 30.69%
2019 493.353.000 30.86%
2020 364.232.000 -35.45%
2021 324.774.000 -12.15%
2022 333.221.000 2.53%
2023 0 0%
2023 4.265.245.000 100%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Unichem Laboratories Limited EBITDA
Year EBITDA Growth
2005 926.990.000
2006 1.033.110.000 10.27%
2007 930.560.000 -11.02%
2008 1.516.654.000 38.64%
2009 1.774.901.000 14.55%
2010 1.569.387.000 -13.1%
2011 1.285.466.000 -22.09%
2012 1.819.256.000 29.34%
2013 1.582.698.000 -14.95%
2014 1.205.171.000 -31.33%
2015 1.830.255.000 34.15%
2016 1.885.302.000 2.92%
2017 -831.528.000 326.73%
2018 21.525.000 3963.08%
2019 151.791.000 85.82%
2020 1.292.478.000 88.26%
2021 1.225.702.000 -5.45%
2022 -371.671.000 429.78%
2023 571.940.000 164.98%
2023 -253.746.000 325.4%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Unichem Laboratories Limited Gross Profit
Year Gross Profit Growth
2005 5.472.620.000
2006 6.279.390.000 12.85%
2007 6.713.490.000 6.47%
2008 7.352.336.000 8.69%
2009 7.473.860.000 1.63%
2010 8.240.381.000 9.3%
2011 5.191.860.000 -58.72%
2012 6.858.535.000 24.3%
2013 7.384.982.000 7.13%
2014 7.525.897.000 1.87%
2015 8.649.490.000 12.99%
2016 9.907.727.000 12.7%
2017 4.065.086.000 -143.73%
2018 6.555.121.000 37.99%
2019 7.470.973.000 12.26%
2020 7.885.479.000 5.26%
2021 8.074.406.000 2.34%
2022 7.920.955.000 -1.94%
2023 10.112.928.000 21.67%
2023 5.339.717.000 -89.39%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Unichem Laboratories Limited Net Profit
Year Net Profit Growth
2005 803.030.000
2006 702.490.000 -14.31%
2007 508.830.000 -38.06%
2008 1.081.552.000 52.95%
2009 1.228.050.000 11.93%
2010 951.959.000 -29%
2011 712.575.000 -33.59%
2012 1.132.258.000 37.07%
2013 1.693.075.000 33.12%
2014 753.901.000 -124.58%
2015 1.080.341.000 30.22%
2016 1.086.751.000 0.59%
2017 25.449.103.000 95.73%
2018 -238.004.000 10792.72%
2019 -601.825.000 60.45%
2020 343.248.000 275.33%
2021 330.617.000 -3.82%
2022 -2.022.276.000 116.35%
2023 -979.516.000 -106.46%
2023 -704.743.000 -38.99%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Unichem Laboratories Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 9
2006 8 -28.57%
2007 6 -40%
2008 12 54.55%
2009 14 15.38%
2010 11 -30%
2011 8 -42.86%
2012 13 41.67%
2013 19 33.33%
2014 8 -125%
2015 12 27.27%
2016 12 0%
2017 281 96.07%
2018 -3 9433.33%
2019 -9 62.5%
2020 5 300%
2021 5 0%
2022 -29 114.29%
2023 -14 -115.38%
2023 -10 -30%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Unichem Laboratories Limited Free Cashflow
Year Free Cashflow Growth
2005 143.420.000
2006 -386.290.000 137.13%
2007 -142.700.000 -170.7%
2008 434.722.000 132.83%
2009 831.940.000 47.75%
2010 -222.904.000 473.23%
2011 109.825.000 302.96%
2012 732.260.000 85%
2013 -172.875.000 523.58%
2014 -5.835.000 -2862.72%
2015 -299.844.000 98.05%
2016 -814.917.000 63.21%
2017 -3.475.015.000 76.55%
2018 -5.220.768.000 33.44%
2019 -3.663.355.000 -42.51%
2020 -2.547.157.000 -43.82%
2021 -3.866.144.000 34.12%
2022 -1.294.064.000 -198.76%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Unichem Laboratories Limited Operating Cashflow
Year Operating Cashflow Growth
2005 419.280.000
2006 478.020.000 12.29%
2007 700.300.000 31.74%
2008 1.027.704.000 31.86%
2009 1.291.013.000 20.4%
2010 685.872.000 -88.23%
2011 1.240.808.000 44.72%
2012 1.712.303.000 27.54%
2013 867.340.000 -97.42%
2014 780.985.000 -11.06%
2015 1.119.126.000 30.21%
2016 683.419.000 -63.75%
2017 -3.475.015.000 119.67%
2018 -3.277.696.000 -6.02%
2019 198.165.000 1754.02%
2020 330.987.000 40.13%
2021 -2.596.120.000 112.75%
2022 -850.907.000 -205.1%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Unichem Laboratories Limited Capital Expenditure
Year Capital Expenditure Growth
2005 275.860.000
2006 864.310.000 68.08%
2007 843.000.000 -2.53%
2008 592.982.000 -42.16%
2009 459.073.000 -29.17%
2010 908.776.000 49.48%
2011 1.130.983.000 19.65%
2012 980.043.000 -15.4%
2013 1.040.215.000 5.78%
2014 786.820.000 -32.2%
2015 1.418.970.000 44.55%
2016 1.498.336.000 5.3%
2017 0 0%
2018 1.943.072.000 100%
2019 3.861.520.000 49.68%
2020 2.878.144.000 -34.17%
2021 1.270.024.000 -126.62%
2022 443.157.000 -186.59%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Unichem Laboratories Limited Equity
Year Equity Growth
2005 3.257.770.000
2006 4.023.940.000 19.04%
2007 4.115.210.000 2.22%
2008 4.844.470.000 15.05%
2009 5.629.130.000 13.94%
2010 6.177.049.000 8.87%
2011 6.605.833.000 6.49%
2012 7.270.719.000 9.14%
2013 8.166.092.000 10.96%
2014 8.675.202.000 5.87%
2015 9.548.356.000 9.14%
2016 10.636.195.000 10.23%
2017 26.800.838.000 60.31%
2018 26.199.069.000 -2.3%
2019 25.313.517.000 -3.5%
2020 25.568.348.000 1%
2021 26.184.110.000 2.35%
2022 24.353.041.000 -7.52%
2023 24.080.111.000 -1.13%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Unichem Laboratories Limited Assets
Year Assets Growth
2005 5.092.580.000
2006 5.949.660.000 14.41%
2007 6.029.430.000 1.32%
2008 7.028.419.000 14.21%
2009 8.006.491.000 12.22%
2010 8.812.950.000 9.15%
2011 9.865.506.000 10.67%
2012 10.725.029.000 8.01%
2013 11.446.538.000 6.3%
2014 11.686.768.000 2.06%
2015 12.842.662.000 9%
2016 15.257.634.000 15.83%
2017 31.889.737.000 52.16%
2018 31.496.115.000 -1.25%
2019 31.447.359.000 -0.16%
2020 31.257.140.000 -0.61%
2021 33.187.743.000 5.82%
2022 31.930.489.000 -3.94%
2023 30.699.339.000 -4.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Unichem Laboratories Limited Liabilities
Year Liabilities Growth
2005 1.621.050.000
2006 1.925.720.000 15.82%
2007 1.914.220.000 -0.6%
2008 2.183.949.000 12.35%
2009 2.377.361.000 8.14%
2010 2.635.901.000 9.81%
2011 3.259.673.000 19.14%
2012 3.454.310.000 5.63%
2013 3.280.446.000 -5.3%
2014 3.011.566.000 -8.93%
2015 3.294.306.000 8.58%
2016 4.621.439.000 28.72%
2017 5.088.899.000 9.19%
2018 5.297.046.000 3.93%
2019 6.133.842.000 13.64%
2020 5.688.792.000 -7.82%
2021 7.003.633.000 18.77%
2022 7.577.448.000 7.57%
2023 6.619.228.000 -14.48%

Unichem Laboratories Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
219.34
Net Income per Share
-18.95
Price to Earning Ratio
-24.26x
Price To Sales Ratio
2.1x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
1.34
EV to Sales
2.24
EV Over EBITDA
233
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
-0.04
FreeCashFlow Yield
0
Market Cap
32,37 Bil.
Enterprise Value
34,64 Bil.
Graham Number
381.98
Graham NetNet
26.54

Income Statement Metrics

Net Income per Share
-18.95
Income Quality
0
ROE
-0.05
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0.85
EBT Per Ebit
-0.66
Ebit per Revenue
-0.02
Effective Tax Rate
0.15

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.6
Operating Profit Margin
-0.02
Pretax Profit Margin
0.01
Net Profit Margin
0.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.04
Return on Tangible Assets
-0.04
Days Sales Outstanding
146
Days Payables Outstanding
121.8
Days of Inventory on Hand
362.24
Receivables Turnover
2.5
Payables Turnover
3
Inventory Turnover
1.01
Capex per Share
0

Balance Sheet

Cash per Share
9,50
Book Value per Share
342,20
Tangible Book Value per Share
341.99
Shareholders Equity per Share
342.2
Interest Debt per Share
44.38
Debt to Equity
0.12
Debt to Assets
0.09
Net Debt to EBITDA
15.27
Current Ratio
2.77
Tangible Asset Value
24,06 Bil.
Net Current Asset Value
8,70 Bil.
Invested Capital
0.12
Working Capital
9,78 Bil.
Intangibles to Total Assets
0
Average Receivables
6,03 Bil.
Average Payables
2,53 Bil.
Average Inventory
6313841000
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Unichem Laboratories Limited Dividends
Year Dividends Growth
2008 6
2009 6 0%
2010 7 0%
2011 3 -200%
2012 3 33.33%
2013 5 25%
2014 8 50%
2015 2 -300%
2016 2 0%
2017 3 33.33%
2018 5 40%
2019 4 -25%
2020 4 0%
2021 4 0%
2022 8 50%

Unichem Laboratories Limited Profile

About Unichem Laboratories Limited

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.

CEO
Mr. Scott B. Delaney
Employee
2.894
Address
Unichem Bhavan
Mumbai, 400102

Unichem Laboratories Limited Executives & BODs

Unichem Laboratories Limited Executives & BODs
# Name Age
1 Mr. Pabitrakumar Kalipada Bhattacharyya
MD & Director
70
2 Mr. Prasad Joshi
Vice President of Human Resources & ER
70
3 Mr. Pradeep Kumar Bhandari
Head of Legal & Company Secretary
70
4 Mr. Bhagwat S. Dhingra
Chief Executive of Domestic Pharma
70
5 Mr. Jalesh Burye
Chief Quality & Compliance Officer
70
6 Dr. Ashwani Kumar
Chief Manufacturing & Compliance Officer
70
7 Dr. Dhananjay Sathe
Chief Scientific & Compliance Officer
70
8 Mr. Scott B. Delaney
President of North America & Chief Executive Officer of North America
70
9 Mr. Sandip Ghume
Deputy Chief Financial Officer
70
10 Mr. Vinod Kumar Behl
Head of Projects & Investments
70

Unichem Laboratories Limited Competitors

Indoco Remedies Limited Logo
Indoco Remedies Limited

INDOCO.NS

(3.2)
Shilpa Medicare Limited Logo
Shilpa Medicare Limited

SHILPAMED.NS

(1.5)
Bliss GVS Pharma Limited Logo
Bliss GVS Pharma Limited

BLISSGVS.NS

(3.2)
Neuland Laboratories Limited Logo
Neuland Laboratories Limited

NEULANDLAB.NS

(3.0)